Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ovarian Neoplasms 4Uterine Cervical Neoplasms 1Malignant Female Reproductive System Neoplasm 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 66Rituximab 43fludarabine phosphate 37Methotrexate 36Whole-Body Irradiation 34Peripheral Blood Stem Cell Transplantation 34Vincristine 33Etoposide 32Cytarabine 29Mycophenolic Acid 28Tacrolimus 23Busulfan 23Prednisone 22Doxorubicin 22Filgrastim 21merphos 20Dexamethasone 20Cyclosporine 19Melphalan 18Calcium Dobesilate 18Granulocyte Colony-Stimulating Factor 17Antilymphocyte Serum 17Radiotherapy 16Leucovorin 15dexamethasone acetate 14dexamethasone 21-phosphate 14auricularum 13prednylidene 12deltacortene 12azathiopurine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Burkitt Lymphoma × Laparotomy × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡